Unexpectedly, despite the documented beneficial role of BCG in bladder cancer, our data indicate that its ability to modify the microenvironment of bladder cancer ex vivo is largely limited to the enhancement of local production of Treg- and MDSC-attracting chemokines, CCL22 and CXCL8, without inducing CXCL10 or facilitating CTL attraction. Here, CCL22 is linked to urinary bladder carcinoma.